Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $45.00 at Oppenheimer

Sarepta Therapeutics (NASDAQ:SRPT) had its target price cut by Oppenheimer from $123.00 to $45.00 in a research report released on Friday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other equities analysts have also issued research reports about the company. Royal Bank Of Canada lowered their price target on Sarepta Therapeutics from $87.00 to $58.00 and set a “sector perform” rating on the stock in a report on Wednesday, May 7th. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Sarepta Therapeutics from $50.00 to $25.00 and set a “hold” rating for the company in a report on Tuesday. Wells Fargo & Company decreased their price objective on shares of Sarepta Therapeutics from $100.00 to $75.00 and set an “overweight” rating on the stock in a research report on Tuesday. Bank of America reiterated a “neutral” rating and set a $28.00 price target (down from $76.00) on shares of Sarepta Therapeutics in a report on Monday, June 16th. Finally, William Blair reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a research report on Friday. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Sarepta Therapeutics has an average rating of “Hold” and an average target price of $67.64.

Sarepta Therapeutics Price Performance

SRPT opened at $20.08 on Friday. The stock’s 50-day moving average price is $43.10 and its 200 day moving average price is $82.89. The company has a current ratio of 4.02, a quick ratio of 2.46 and a debt-to-equity ratio of 1.00. Sarepta Therapeutics has a 12-month low of $18.30 and a 12-month high of $173.25. The firm has a market cap of $1.97 billion, a price-to-earnings ratio of -7.46 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million during the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The company’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 earnings per share. As a group, sell-side analysts expect that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Trading of Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SRPT. EP Wealth Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock valued at $606,000 after acquiring an additional 105 shares during the last quarter. CIBC Asset Management Inc boosted its position in Sarepta Therapeutics by 5.1% during the fourth quarter. CIBC Asset Management Inc now owns 2,851 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 139 shares during the period. PNC Financial Services Group Inc. boosted its position in Sarepta Therapeutics by 5.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 145 shares during the period. Virtus ETF Advisers LLC grew its holdings in Sarepta Therapeutics by 6.6% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,809 shares of the biotechnology company’s stock valued at $342,000 after purchasing an additional 174 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC raised its position in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.